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Abstract
Glioma is the most common primary tumor in the central nervous system (CNS). Even
with aggressive treatments, gliomas remain as one of the most devastating tumors.
Chemotherapy through oral administration of temozolomide (TMZ) is currently the
standard regimen for malignant gliomas. However, the systemic toxicity and drug
resistance are frequently observed in glioma patients. In order to improve the efficacy
and minimize side effects, multiple strategies have been developed. Interstitial chemo‐
therapy is a promising one. By directly delivering chemotherapeutic agents in tumor bed,
interstitial chemotherapy bypasses the blood–brain barrier (BBB) and therefore achieves
a higher concentration with less systemic exposure. In this chapter, we will have a thorough
review on the development and the application of interstitial chemotherapy in gliomas,
with the focus on the biomaterial‐based and convection‐enhanced delivery system. In
addition, the future of interstitial chemotherapy is also be shortly discussed.
Keywords: malignant gliomas, local therapy, surgery, adjuvant chemotherapy, temo‐
zolomide, Gliadel waffer
1. Introduction
Malignant gliomas account for more than 50% of primary central nervous system (CNS) tumors
and are among the most formidable cancers in human beings (1). Although aggressive debulking
surgery followed by radiation and chemotherapy is the mainstay for malignant gliomas, the
prognosis of malignant gliomas remains far from satisfactory. The 5‐year overall survival (OS)
is as low as 9.8% for patients with glioblastoma multiforme (GBM), a malignancy classified as
grade IV by the world health organization (WHO) (2). The recurrence seems to be inevitable for
malignant gliomas. Most patients with recurred GBM will die within 6 months even with salvage
treatments.
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The exact mechanisms underlying the intractability of malignant gliomas have not been fully
understood, but the inherent resistance and the sheltering environment of brain have been
proposed to protect the disease from conventional treatments. First of all, the infiltrative
growth pattern of glioma cells makes the complete surgical resection almost impossible.
Second, the existence of blood–brain barrier (BBB), which is tightly formed by capillary
endothelial cells together with astrocytes, restricts the entry of most systemically adminis‐
tered chemotherapeutic agents into the tumor parenchyma (3). Third, the inherent and
acquired insensitivity to radiation and chemotherapy through the disturbance of signaling
pathway in glioma cells results in the resistance to current therapies (4). Because gliomas
seldom metastasize outside the CNS and usually recur within 1–2 cm from the original tumor
site, it is reasonable to expect the efficacy of directly delivering potent chemotherapeutic drugs
into the tumor mass and its adjacent area. By this means, not only a higher drug concentra‐
tion around the tumor but also a minimal systemic toxicity can be achieved.
2. Early experience
2.1. Topical application
Various methods have been attempted for locoregional therapy. The initial experience started
with topical application. In 1963, Heppner and Diemath (5) treated brain tumor patients with
local chemotherapy by placing gelatin sponges soaked with endoxan. Similarly, Ringkjob
applied gelatin sponges filled with cytostatic agents including 5‐fluorouracile (5‐FU),
methylene hydrazine, and thiophosphoramide to the resection cavity in patients with gliomas
and brain metastases (6). Although the adverse effects were minimal in both studies, the clinical
benefits were either hard to define or inappreciable. As a result, topical application of
chemotherapeutics was gradually disregarded.
2.2. Direct injection
Direct injection is another early strategy to give local therapy. A subcutaneous reservoir (e.g.,
Ommaya reservoir) is implanted with its catheter into the resection cavity during surgery of
brain tumors. Repeated injection of multiple chemotherapeutic agents can be done trough the
reservoir postoperatively. Because direct injection is easy and repeatable, a number of studies
have been done to explore the efficacy. In a Phase I/II trial, Boiardi et al. (7) implanted Ommaya
reservoir in 12 patients with recurred malignant glioma. Two cycles of mitoxantrone were
directly delivered into intratumoral cavity through Ommaya reservoir with or without
systemic chemotherapy. The treatment was well tolerated in all patients. Either response or
stable disease was found in 9 of 12 patients. A Japanese group investigated the histopatho‐
logical changes after local chemotherapy via Ommaya reservoir (8). Massive coagulation
necrosis surrounded by abundant reactive collagenous tissues, gliomesenchymal tissue, and
infiltrating lymphocytes was found in the tumor bed, especially in areas around the catheter
tip of Ommaya reservoir. This finding suggested the effectiveness of local chemotherapy. In
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2008, Boiardi and colleagues (9) reported a non‐randomized study with a large sample size.
Two hundred and seventy‐six patients with recurrent GBM were enrolled. Among them, 161
cases (Group A) were only treated systemically with oral temozolomide (TMZ), while 50
patients (Group B) were re‐operated and received TMZ therapy postoperatively, and 50
cases (Group C) were treated with re‐operation, postoperative TMZ, and locoregional therapy
with mitoxantrone. The overall survival for Group C, B, and A was 27, 26, and 15.5 months,
respectively (p = 0.1). The median survival after tumor recurrence was 16.8, 12, and 6.6 months
for Group C, B, and A (p = 0.001), respectively. The authors therefore suggested that a second
surgery combined with local chemotherapy would prolong the survival of patients with
recurrent malignant gliomas.
In addition to chemotherapeutics, other agents have also been investigated for local therapy
via direct injection. For example, Mamelak and colleagues (10) evaluated the safety and
biodistribution of iodine‐131 (131I)‐TM‐601, a synthetic radioiodinated targeting peptide, for
recurrent malignant gliomas in a Phase I trial. A total of 18 patients received a single dose of
131I‐TM‐601 from one of the three dosing panels (0.25, 0.50, or 1.0 mg of TM‐601). The agent
was injected into the tumor cavity via a subcutaneous reservoir 2 weeks after surgery. The
dosimetry analysis demonstrated a long‐term retention of the agents around the injection site.
The median half‐life in the cavity margin was more than 50 h. No severe adverse effects were
found during the delivery. Among 11 patients who completed the 180‐day follow‐up, two
patients with recurrent GBM survived more than 30 months. The median survival was as long
as 77.6 weeks in a subgroup of patients who received 0.5‐mg dose of 131I‐TM‐601. In another
study, Prados and colleagues investigated the safety and efficacy of local gene therapy in
recurrent GBM patients. Virus‐producing cells (VPC) containing the herpes simplex virus
thymidine‐kinase (HSV‐Tk) gene were injected into tumor cavity directly during debulking
surgery and postoperatively via reservoir, followed by ganciclovir treatment (11). Among 30
patients enrolled in the study, 16 had severe adverse events such as infection, skin necrosis,
and myelosuppression. The median survival of the series of 30 patients was 8.4 months. Six
patients (20%) survived more than 1 year from the date of enrollment. The authors conclud‐
ed that the direct delivery of gene therapy demonstrated some evidence of efficacy, while the
improvement of procedures was needed to decrease the toxicity. Other studies also evaluat‐
ed the feasibility to treat gliomas locally with immunotherapeutic agents such as autologous
lymphocytes and immunomodulators (12, 13).
Although antecdotal reports of success achieved by direct injection of chemotherapeutics for
glioma patients can be frequently found in literatures, no large‐scale well‐designed Phase III
trial has been ever performed. In fact, local chemotherapy through direct injection has its own
limitations. Firstly, repeated puncture and injection through the reservoir are associated with
increased risk of intracranial infection and hemorrhage. Secondly, the injected drugs hetero‐
geneously distribute in the tumor cavity through this approach. A sharp drug distribution
gradient has been found, with an extremely high concentration around the tip of the cathe‐
ter and a significant drop in the adjacent area. Therefore, the clinical exploration of local
chemotherapy via direct injection dramatically declined.
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3. Polymeric drug delivery
3.1. History
In order to overcome the drawbacks mentioned above and to achieve the local controlled
release of chemotherapeutics, efforts have been made to develop delivery system with
synthetic polymers. Early in 1970s, an ethylene vinylacetate copolymer (EVAc) was em‐
ployed to generate a poriferous matrix and incorporate macromolecules such as chemothera‐
peutics (14). The impregnated agents are released from the matrix in a predictable and
sustained style by diffusion. The rate of release depends on the physicochemical property of
the agents, such as solubility, charge, and molecular weight. However, EVAc was restricted
by the non‐degradable nature and was therefore seldom used in neuro‐oncology.
3.2. Carmustine implants
3.2.1. Background information
Various biodegradable polymers, such as the 1,3‐bis(p‐carboxyphenoxy) propane and sebacic
acid (PCPP‐SA), the fatty acid dimer sebacic acid (FAD‐SA), and poly(lactide‐co‐glycolide)
(PLGA) polymers, have been investigated in the last 3 decades. But until now, PCPP‐SA is the
most successful and widely used polymer for brain tumors. This compound has several
advantages as matrix (15). Firstly, PCPP‐SA is hydrophobic and can therefore protect the
impregnated drug from inactivation by the surrounding aqueous environment. Secondly, the
two‐stage degradation of PCPP‐SA matrix results in the gradual release of the content. At the
first stage, the bonds between sebacic acid and sebacic acid or those between sebacic acid and
CPP rapidly hydrolyzed, whereas the bonds between CPP and CPP take a longer time to
degrade. This initial degradation is followed by a process of inward erosion which starts at
the surface of the matrix and goes interiorly into the core. By modulating the ratio of sebacic
acid and CPP in the matrix, the speed of degradation can be adjusted from hours to days as
required. In addition, the breakdown of the PCPP‐SA does not leave foreign body behind.
Currently, the only US Food and Drug Administration (FDA) approved local chemothera‐
peutical agent for brain tumors, that is, Gliadel wafer, is composed by PCPP‐SA as matrix
and 1,3‐bis(2‐chloroethyl)‐1‐nitrosurea (carmustine or BCNU) as content.
BCNU is one of the most effective chemotherapeutics against malignant brain tumors at the
time when the first local polymeric drug delivery system was being developed. BCNU is a
classic alkylating and exerts its anti‐tumor effect by forming inter‐strand crosslink in DNA and
subsequently inhibiting the replication and transcription of DNA in tumor cells (16). The
highly lipid‐soluble and nonpolar nature of BCNU makes it ideal for cancers in CNS be‐
cause the agent has a good penetration of BBB. The concentration of BCNU in cerebral spinal
fluid (CSF) is as high as 30% of that in plasma after intravenous injection. Clinical studies have
demonstrated that systemic administration of BCNU is capable of prolonging the survival of
patients with malignant gliomas (17). As a result, BCNU alone or combined with other agents
has once been the most frequently used chemotherapy regimens for malignant gliomas.
Although effective, intravenously administered BCNU is limited by its toxicities (18).
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Gastrointestinal adverse effects such as nausea and vomiting can be observed shortly after
infusion of BCNU and last for hours. Systemic BCNU therapy also causes myelosuppression.
The peak of hematologic suppression may occur 1 month after BCNU administration, and it
may take weeks for the recovery of bone marrow. In addition, pulmonary injury is another
toxicity caused by BCNU treatment. Although rare, with the occurrence of approximately 5%
of the patients, the BCNU‐associated pneumonitis induces restrictive pulmonary disorders
and subsequently progressive lung fibrosis, even after the withdrawal of the agent. Some
patients terminate the chemotherapy due to the severe and irreversible toxicities. Based on its
clinical efficacy against malignant brain tumors and the undesirable adverse effects, BCNU
was impregnated into the PCPP‐SA polymers. The BCNU wafers were explored for preclini‐
cal testing followed by clinical investigation.
3.2.2. Preclinical evidence
Preclinical exploration established the safety of the wafers in the CNS. Brem and colleagues
(19) implanted the PCCP‐SA polymers in the frontal lobe of rabbits and evaluated the
biocompatibility. No neurological deficits or behavioral abnormalities suggestive of toxicity
were observed. All the tested animals survived to the date of sacrifice. The histological analysis
revealed that the inflammatory reaction from PCCP‐SA was not significantly different from
that in the controlled group implanted with Gelform, a widely used hemostatic material in
neurosurgical operations. In primate models, the interstitial chemotherapy with BCNU
polymers alone or combined with external beam radiation was found to be safe. The local‐
ized inflammatory response induced by BCNU wafers was well tolerated and manageable (20).
The in vivo experiments were also performed to evaluate the pharmacokinetics of BCNU
wafers. In a rat model, the concentration of radiolabelled BCNU on the coronal sections of the
brains was measured (21). BCNU delivered by polymers was at a concentration of 1 mM
around the implanted site for the entire 30‐day experiment. On day one, after implantation,
BCNU penetrated the brain at a radius of 5 mm at a significant concentration, which was
defined as 10% of the maximum concentration at the brain/polymer interface. Grossman and
colleagues (22) investigated the intra‐cerebral drug distribution in rabbits after the implanta‐
tion of BCNU wafers. Radiolabeled BCNU was detected in 50% the area of the brain sections
3 days after BCNU‐polymer implantation. On day seven, the concentration of BCNU was as
high as 6 mM at the distance of 10 mm from the implantation site, which is far more than the
active concentration of 14–16 μM against glioma cells in vitro. Because BCNU impregnated in
polymers is released in a controlled manner, Fung and colleagues (23) calculated and
compared the area under curve (AUC, concentration over time) of BCNU delivered by
polymers to monkey brain and that administered by intravenous injection. In that study,
polymeric BCNU delivery was estimated to achieve a 4-fold larger AUC in distant sites of brain
and as high as 1200‐fold more at the brain/polymer interface, in comparison with the conven‐
tional intravenous administration.
The efficacy of interstitial chemotherapy with BCNU was then tested in animal models.
Tamargo and colleagues (24) demonstrated that local delivery of BCNU via polymers
significantly prolonged the survival of rats intracranially implanted with 9 L gliosarcoma cells,
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compared with intraperitonal injection of the agent. The median survival of animals treated
with BCNU polymers was 62 days, which was more than double that for rats treated with
systemic administration. In another study with the rat orthotopic glioma model, BCNU‐
impregnated polymers were found to be superior to extend the lifespan of tumor‐bearing rats,
compared with the direct injection of BCNU into the tumor tissues (25).
3.2.3. Clinical trials
The preclinical evidence of the safety and the effectiveness of polymeric BCNU delivery
rationalized the investigation of the clinical benefit of this therapy. Brem and colleagues
reported a multicenter Phase I–II trial with BCNU polymers in recurrent glioma patients. In
that study, twenty‐one patients with recurrent malignant glioma were enrolled (26). Up to 8 
BCNU polymer wafers with three escalating concentrations, that is, 1.93, 3.85, and 6.35%, were
implanted in the tumor beds. The authors demonstrated that the local treatment with BCNU
was well tolerated, and no systemic adverse effects related to the therapy were observed in all
patients. The study also recorded the survival outcome. The average survival time was 65, 64,
and 32 weeks for patients treated with the low, medium, and high concentration of BCNU,
respectively. Based on the result of this study, the further efficacy evaluation employed
polymeric wafers with the 3.85% dose of BCNU. However, it is worth noting that patients
treated with the highest dose of BCNU in the study had the shortest survival, which was not
due to the adverse effects. In fact, the small sample size and the difference in the grade of
gliomas among three groups account for the paradox. The group treated with the highest dose
composed a higher proportion of GBM than the other two groups. In another multicenter
single‐arm Phase I trial, Brem and colleagues (27) demonstrated that the placement of
polymeric BCNU wafers followed by the external radiation was safe for newly diagnosed
malignant gliomas.
The role of interstitial chemotherapy with BCNU in recurrent malignant glioma was ex‐
plored in a multicenter, double‐blinded, placebo‐controlled trial of 222 patients from 27
centers (28). Biodegradable polymers with 3.85% BCNU or empty polymer wafers were
randomly implanted in the tumor site after resection. One hundred and ten patients re‐
ceived BCNU polymers and 112 had placebo‐wafers. The median survival of patients with
BCNU wafers was 31 weeks, which is superior to 23 weeks for patients with empty poly‐
mers (HR = 0.67, p = 0.006, after accounting for the effects of prognostic factors). Among 212
patients, 145 (65.3%) had pathologically confirmed GBM. Significantly reduced mortality at
6 months was observed in GBM patients treated with BCNU wafers (44%, 32 of 72 cases) than
those treated with placebo implants (64%, 47 of 73 patients, p = 0.02). As a result, FDA approved
the use of 3.85% BCNU wafers (Gliadel®) for recurrent malignant gliomas. However, a recent
meta‐analysis from the Cochrane library doubted the benefit of BCNU wafers in the treat‐
ment of recurrent malignant gliomas (29). No statistical difference in survival was found
between patients treated with Gliadel® and those with placebo (HR = 0.83, 95% CI 0.62–1.10, p
= 0.2). The acquired chemoresistant by the point of the implantation of BCNU wafers and the
treatment‐associated changes, such as the radiation‐induced gliosis, which may restrict the
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diffusion of BCNU around the resection cavity, was suggested to be responsible for the
ineffectiveness.
Efforts have also been put to investigate the efficacy of BCNU wafers as the initial treatment
for newly diagnosed malignant gliomas. Two phase III multicenter, double‐blinded, placebo‐
controlled trials drew the similar conclusions. In 1997, Valtonen and colleagues (30) publish‐
ed the study that was prematurely terminated due to the unavailability of the wafers. Thirty‐
two patients (16 in each group) with newly diagnosed malignant gliomas were randomly
assigned to the active treatment group with BCNU wafers or the placebo group at the time of
the primary surgery. An improved survival was observed in active treatment group (58.1 
weeks), compared with the placebo group (39.9 weeks) (p = 0.012). For the subset of patients
with GBM, BCNU wafers also offered survival benefit compared with placebo (53.3 vs. 39.9 
weeks, p = 0.008). To confirm this positive result, a Phase III clinical trial with a larger sam‐
ple size of 240 patients with newly diagnosed malignant glioma was subsequently per‐
formed (31). Patients randomly received the placement of either BCNU or empty polymers in
the tumor bed, followed by the postoperative external radiation therapy. Prognostic factors,
such as age, sex, Karnofsky performance status (KPS), and tumor grading, were balanced. The
BCNU‐treatment group had a significantly longer median survival (13.9 months) than placebo
group (11.6 months) (p = 0.03). The risk of death was reduced by 29% in the treatment group.
More adverse events including symptomatic intracranial hypertension (9.1 vs. 1.7%) and CSF
leaking (5 vs. 0.8%) were observed in patients treated with BCNU wafers. In 2003, FDA granted
the approval of Gliadel® wafers to treat newly diagnosed malignant gliomas. Until now,
Gliadel® wafers are commercially available in the United States, Canada, Europe, and Japan
for the adjuvant treatment of newly diagnosed malignant gliomas.
A preclinical works have revealed that the anti‐glioma effect positively related to the load‐
ing dose of BCNU in biodegradable polymers in primate models (32). The question of whether
a higher concentration of BCNU for interstitial chemotherapy is safe and capable of prolong‐
ing the overall survival of glioma patients was raised. The New Approaches to Brain Tumor
Therapy (NABTT) CNS Consortium therefore investigated the safety of polymer wafers with
higher concentrations of BCNU in a dose escalation trial (33). Forty‐four patients with
malignant gliomas were treated with polymer wafers containing BCNU at escalating doses
of 6.5, 10, 14.5, 20, and 28%, respectively. The authors demonstrated that BCNU‐impregnat‐
ed wafers with a higher concentration of up to 20%, which was more than five times the dose
of commercially available Gliadel®, were safe. The median OS of the patients after the
placement of BCNU wafers was 251 days. Although further large‐scale trials were suggested
to explore the efficacy of high‐dose BCNU wafers, the group has not initiated any of the studies.
Recently, we evaluated the safety of high‐dose BCNU‐loaded biodegradable wafers in Chinese
patients with recurrent malignant glioma (34). The wafers we used are comprised of poly
(lactide‐co‐glycolide) (PLGA) containing 10% BCNU. PLGA is also a FDA approved materi‐
al for drug delivery, which has more tunable mechanical properties and can be stored at 2–
10°C in comparison with PCCP used in Gliadel®. In addition, PLGA degrades directly into
water and carbon dioxide and does not need clearance in liver or kidney. The dosage of 10%
BCNU is 2.5 times that of Gliadel®. Our study demonstrated that 12 implants with 240 mg
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BCNU was well tolerated in tested patients. No dose‐limiting toxicity was found. The median
survival of this cohort of patients was 322 days. The 6‐months, 1‐year, and 2‐year survival rates
were 66.7, 40, and 13.3%, respectively. A registered double‐blinded randomized Phase III trial
is on‐going to investigate the efficacy of the high‐dose BCNU‐impregnated PLGA wafers for
recurrent malignant gliomas.
In 2005, Stupp and colleagues (35) published the milestone Phase III trial on the efficacy of
adjuvant chemotherapy with temozolomide (TMZ) for GBMs. TMZ is a second generation
alkylating agent, which can be administered orally. The Stupp regimen, that is, the concur‐
rent chemoradiation with TMZ followed by six cycles of adjuvant TMZ, offered a modest but
statistically significant extension of the survival of patients with GBM. As a result, TMZ is
currently the standard‐of‐care for GBMs. The preclinical data presented by Plowman and
colleagues (36) revealed that sequential administration of BCNU and TMZ resulted in a
dramatic synergism and significantly inhibited the growth of glioma xenograft in mice. At the
time when TMZ emerges, the safety profile and treatment outcome of TMZ with additional
Gliadel® wafers was unclear. Gururangan and colleagues (37) investigated the safety of TMZ
combined with BCNU wafers in a dose‐escalation trial. Ten patients with recurrent malig‐
nant glioma were treated with BCNU implants followed by oral administration of TMZ at
daily dose of 100, 150, and 200 mg/m2, respectively. The combined treatment was well
tolerated. Only one patient treated with TMZ at the highest daily dose of 200 mg/m2 suf‐
fered from grade III thrombocytopenia. Until now, no randomized Phase III trial has been
conducted to explore the efficacy of combined therapies in comparison with either TMZ or
Gliadel® alone. Several prospective and retrospective studies with small number of patients
indicated that sequential treatment with Gliadel® and TMZ resulted in an incremental gain
of 2–3 months in median survival (38). Although the level of clinical evidence is not high
enough, the combined treatment with Gliadel® and TMZ is currently recommended as an
active option for newly diagnosed and recurrent malignant gliomas by the National
Comprehensive Cancer Network (NCCN) guidelines (39).
3.2.4. Prevention for complications
The implantation of BCNU wafers is generally safe, but clinical lessons have been learned from
the employment of Gliadel® for the management of malignant gliomas. The common ad‐
verse effects include healing abnormalities, seizures, and intracranial hypertension (40).
Several strategies have been suggested to decrease the risks associated with BCNU implants
(41). After the resection of the tumor, BCNU wafers should line up the surface of the tumor
bed. Stack of the implants should be avoided because the stacking may result in an irregular
release of BCNU due to the altered degradation kinetics of polymers. A large communica‐
tion between resection cavity and ventricle is the contraindication for wafer implantation. The
unexpected translocation of BCNU wafers into ventricle may lead to the life‐threatening
hydrocephalus. In addition, a watertight closure of the dura is critical to avoid CSF leak and
decreases the risk of healing abnormalities and infection. Perioperative anti‐convulsants are
necessary to prevent seizures. Since the implantation of BCNU wafers is associated with
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increased risk of cerebral edema and intracranial hypertension, steroid is suggested to continue
for at least 2 weeks after surgery.
3.2.5. Economic consideration
Although effective, BCNU wafers are expensive for the treatment of malignant gliomas. Much
attention should be paid to the financial implication of the use of BCNU wafers. Rogers and
colleagues (42) conducted a cost‐utility analysis. The authors demonstrated that neurosur‐
gery with Gliadel® implantation followed by radiation therapy costs 54,500 English pounds
per additional quality‐adjusted life‐year (QALY) gained in comparison with surgery com‐
bined with radiotherapy alone. Probabilistic sensitivity model revealed a <10% probability that
Gliadel® would be considered as cost‐effective at a willingness‐to‐pay threshold of 30,000
English pounds per QALY. The authors concluded that Gliadel® is not cost‐effective for
healthcare resources but can be considered as an alternative adoption for the dreadful disease
with a shortage of effective treatments.
3.2.6. Future prospects
Gliadel® represents the first success of the interstitial chemotherapy with biodegradable
polymers. With the increased understanding of glioma biology and the advances in pharma‐
ceutical technology, exploration of how to improve the efficacy of polymeric drug delivery is
on the way. For example, O6‐alkylguanine‐DNA alkyltransferase (AGT) is a well‐known DNA
repair protein, which protects tumor cells from damage through removing O6‐alkylguanine
lesions introduced by alkylating agents such as BCNU and TMZ (43). Brain tumors, especial‐
ly malignant gliomas, are rich in AGT. The level of AGT is negatively associated with the
prognosis of patients with malignant glioma, who receive BCNU therapy (44). Therefore, the
inhibition of AGT is a promising strategy to reverse the resistance of glioma cells to BCNU.
Quinn and colleagues (45) reported the results of a Phase II trial to test the efficacy of the
combination of O6‐benzylguanine (O6‐BG), an AGT inhibitor, with BCNU implantation. Fifty‐
two patients with recurrent malignant glioma were treated with infusion of O6‐BG and
implantation of Gliadel® wafers. The median OS was 50.3 weeks, and the 1‐ and 2‐year OS
was 47 and 10% respectively, which suggested the potential clinical benefit. In addition,
various chemotherapeutic agents other than BCNU have been exploited to deliver through
polymeric system. Preclinical studies demonstrated that many drugs such as temozolomide,
paclitaxel, taxotere, and camptothecin were efficacious against gliomas through polymeric
delivery (46–49). Further clinical investigation of the safety and efficacy is therefore warranted.
4. Convection‐enhanced delivery
4.1. Basic concepts
Convection‐enhanced delivery (CED) is a catheter‐based direct drug microperfusion
technique, which was introduced by Bobo (50). CED continuously infuses soluble therapeutic
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agents into targeted site in CNS through fine catheters implanted either by surgery or
stereotaxis. The hydrostatic pressure gradient (bulk flow) in CED is generated through a
motor‐driven pump connected to the catheters. CED has several advantages as compared with
other drug delivery methods. First of all, CED bypasses BBB and targets tumor bed through
the implantation of catheters. The local concentration achieved by CED can be orders of
magnitude higher than that produced via intravenous injection, while the systemic toxicity is
minimal. Secondly, the pressure‐driven CED creates a homogeneous distribution of infused
agents in a large region in brain while the diffusion‐driven drug delivery such as polymeric
wafers usually leads to a limited penetration from the diffusive interface. A dramatic drop‐
off (250‐ to 1000‐fold decrease) in concentration was observed with the polymeric delivery in
the tissue 1–2 mm away from the surface (51). Thirdly, a very large volume of infusion can be
achieved via CED. It has been demonstrated that a volume of 200 ml infusion into brain did
not cause irreversible neurological deficits in patients with brain tumors (52). Finally, various
agents with different molecular weights such as conventional chemotherapeutical drugs, small
molecular inhibitors, and immunotoxins can be readily infused through CED. Whereas
sophisticated technologies are required to integrate those agents into polymeric system.
4.2. Determining variables for infusate distribution
Several critical factors will influence the distribution of infusate delivered by CED. These
include (i) infusion rate and volume; (ii) catheter features; (iii) anatomical structure and
interstitial fluid pressure; (iv) intrinsic characteristics of infusate.
The concentration differential is the key driving force for diffusion‐driven drug delivery such
as polymeric chemotherapy. By contrast, CED is a method to deliver agents mainly depend‐
ent on pressure gradient in the interstitial space. As a result, the distribution volume of infusate
is mainly determined by infusion volume and rate. In an animal model, the distribution volume
correlates with infusion volume in a linear manner. However, this dependence of infusate
distribution on volume of infusion disappears due to the infusate reflux along the catheter/
brain interface (backflow) when the infusion rate reaches a threshold (e.g., >0.5 μl/min).
Therefore, the optimal infusion rate and volume facilitate a better distribution of infusate.
Backflow is one of the major barriers for the clinical usage of CED. The reflux of infusate not
only reduces the concentration of delivered drugs in the target location but also increases the
risk of adverse effects such as chemical meningitis due to the leakage of the agents into the
subarachoid spaces. The properties of the implanted catheters such as shape and size, and the
implantation method of the catheters are associated with the incidence of backflow in CED.
At the early stage of CED, the open‐ended straight catheters were used, but the backflow was
frequently observed even at a relatively low infusion rate. A systemic analysis demonstrated
that the diameter of catheters positively correlates with the backflow (53). Catheters with the
diameter of <1 mm significantly minimize the backflow and achieve better drug distribution
(54). It has been suggested that a smaller size of the catheter introduces less tissue displace‐
ment and trauma, consequently reducing the backflow. Fiandaca and colleagues modified the
shape of the catheter by developing a step design. The step catheter consists of 0.2 mm needle
with a glued‐in, internal silica tube (0.102‐mm inner diameter) that extends beyond the end of
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the needle by 5–10 mm (55). The authors demonstrated that the step catheter was reflux‐
resistant even when the infusion rate increased to as high as 5 μl/min. Gill and colleagues (56)
evaluated the performance of CED with a recessed‐step catheter, which incorporates an
indwelling catheter with adjustable winged stop within a guide tube. This novel design
showed a superior control of backflow in comparison with the conventional step catheter.
Other catheter designs such as hollow fiber catheter, multiple port catheter, and balloon‐tipped
catheter have also been developed to minimize reflux and improve drug distribution (57).
The tissue structure and pathology at the targeting site are critical factors that influence the
topography and the drug distribution achieved in CED. Normal brain tissues have signifi‐
cant heterogeneity and anisotropy in architecture and permeability for fluid flow. Anatomi‐
cally, grey matter is mainly composed of glial cells and neuron somas, and the effective
diffusivity is generally isotropic in grey matter. Whereas, white matter comprises bundles of
axons connecting various grey matter areas to each other in brain. The permeability varies in
white matter, primarily depending on the density and directional alignment of axon fibers (58).
The diffusion of infusate is anisotropic in white matter. In addition, morphological analysis
and mathematical models revealed that extracellular space is more easily extended by infusion
fluid in white matter than that in grey matter (59, 60). As a result, white matter is more
susceptible to extracellular bulk flow and infusate can travel a longer distance because of the
higher permeability along the white matter. In pathological tissues such as gliomas, the bulk
flow can be less predictable due to the heterogeneous cytoarchitecture and the treatment‐
related changes. GBM is characterized with the thriving growth of tumor cells, pseudopali‐
sading necrosis, and glomeruloid vascular proliferation in histology (61). Interstitial fluid
pressure (IFP) has been found to increase in intracranial tumors in preclinical models and
patients (62). The leaky vasculature coupled with the resistance to bulk flow in the tortuous
interstitial space of the surrounding grey and white matter is suggested to be the underlying
mechanism for the increased IFP in GBMs (63). More importantly, IFP varies in different areas
of the tumor. IFP elevates in the tumor center and dramatically drops toward the tumor
periphery or the surrounding normal brain tissue. The outward pressure gradient restrains
infusate to enter the tumor core, and the leaky tumor vasculature facilitates the rapid efflux of
infused drugs into systemic circulation. Treatment‐induced changes may also complicate the
drug delivery in CED. For example, postoperative inflammatory reaction decreases the
diffusion of drug with a larger molecular weight in extracellular spaces (64). In addition, to
treat a residue tumor surrounding the resection cavity, which directly communicates with the
subarachnoid space or ventricle, makes it more difficult to deliver drugs via CED. The numbers
and placement of catheters should be carefully planned according to the postoperative tumor
characteristics.
Besides, the intrinsic features such as the physical and chemical properties of infusate are
highly related to the efficiency of CED. Drugs with small molecular weight can be employed
in CED, but their faster clearance from CNS limits their diffusion. Agents that easily cross the
BBB are not good choices for CED because they can be readily eliminated from the CNS and
transported into the systemic circulation. Similarly, drugs that are rapidly taken up or
metabolized in the CNS may reduce the distribution of the infusates. Viscosity is also an
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important factor for bulk flow in CED. Intuitively, the less viscous the infusate is, the more
smoothly it diffuses in the extracellular space. Subsequently, a larger diffusion volume is
expected from the low‐viscosity drugs. However, Mardor and colleagues (65) demonstrated
in a rat model that agents with high viscosity tend to have an increased volume of diffusion
because they are more resistant to backflow. Therefore, when a drug is chosen as a candi‐
date for CED, its physico‐chemical characteristics such as molecular weight, viscosity,
clearance rate should be taken into account. In addition, novel strategies are explored to
improve the efficacy of CED through delaying the degradation or clearance of agents in the
target sites. To achieve this goal, drugs are conjugated or encapsuled with nanoparticles or
liposomes (66, 67).
4.3. Agents for convection‐enhanced delivery
A wide range of therapeutic agents, such as conventional chemotherapies, targeted toxins,
viruses and oligonucleotides, have been investigated on CED for the safety and efficacy in the
treatment for gliomas in clinical trials.
4.3.1. Conventional chemotherapeutics
Topotecan, a topoisomerase I inhibitor, is an ideal conventional chemotherapeutic agent for
CED. Firstly, topotecan is more readily to accumulate in gliomas than in normal brain tissue.
Secondly, it specifically kills glioma cells and is less toxic to normal brain. In addition,
topoisomerase I is a natural‐product agent with a high molecular weight. As a result, topote‐
can is difficult to bypass BBB when administered intravenously. Whereas topotecan is less
easily removed into systemic circulation and can be retained in the targeted site for a pro‐
longed time when it is infused via CED. Jeffery and colleagues conducted a Phase Ib trial to
deliver topotecan to recurrent malignant gliomas (68). Sixteen patients were enrolled in that
dose‐escalation trial. The treatment was well tolerated with the stable maintenance of quality
of life and neurocognitive functioning of patients. Tumors substantially regressed without
significant systemic and neurocognitive adverse effects in selected patients with recurrent
malignant gliomas refractory to conventional treatment. The total response of the single
topotecan infusion was 69%. The results were encouraging for relapse patients in whom
previous treatment had failed, but the efficacy of this treatment requires to be confirmed in
Phase II and III trials.
Another conventional chemotherapeutic agent, paclitaxel, has also been delivered through
CED to treat malignant gliomas. In a Phase I/II trial, a total of 20 cycles of intratumoral CED
of paclitaxel was administered to 15 patients with histologically confirmed recurrent GBM (69).
Among these 15 patients, complete response was observed in five cases and partial response
in six cases, respectively. The response rate reached 73%. The poor response seemed to be
associated with the backflow of paclitaxel into subarachnoid spaces, ventricles, and resec‐
tion cavities. Although effective, the local delivery of paclitaxel caused significant incidence
of complications including transient chemical meningitis in six patients, infection in three
patients and transient neurological deficits in four patients. The treatment‐related side effects
have been suggested to be the results of infusate reflux. Strategies such as sealing the burr hole
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with bone wax and adapting the concentration of paclitaxel were used to prevent the extrac‐
ranial leakage of the cytotoxic drug and minimize the treatment‐induced side effects (70).
4.3.2. Targeted cytotoxins
Targeted cytotoxins represent a novel class of agents with high specificity for brain tumors.
The potent protein toxins produced by bacteria are conjugated to carrier ligands, which
specifically bind to the receptors on the surface of glioma cells. Less resistance to targeted
cytotoxins was observed in glioma cells because the agents kill glioma cells through irrever‐
sible de novo protein synthesis, independent of any malignancy‐associated genetic alterations.
The relatively small molecular weight and the highly soluble proteinaceous nature of targeted
cytotoxins make them attractive for CED.
TF‐CRM107 is the first targeted cytotoxin investigated in clinical trials. The agent is com‐
posed of diphtheria toxin conjugated to transferrin‐C and preferentially targets glioma cells
due to the increased expression of transferrin receptor in tumor tissue. Preclinical works
demonstrated that TF‐CRM107 eliminated glioma cells at picomolar concentrations in vitro
and significantly inhibited the growth of subcutaneous glioma xenografts in a mouse model
(71, 72). Delivery of TF‐CRM107 through CED was safe for patients with malignant brain
tumors. In a dose‐escalating trial, the treatment was well tolerated (52). No significant
neurological and systemic adverse events were observed. In the subsequent Phase II trial, 44
patients with refractory and recurrent malignant gliomas were enrolled (73). TF‐CRM107
(concentration of 0.67 μg/ml) was delivered continuously through CED at a rate escalating up
to 0.2 ml/h per catheter (a total of 0.4 ml/h for 2 catheters) until a volume of 40 ml was infused.
The outcome was encouraging, with a total response of 35% and a median survival of 37 weeks.
Unfortunately, the multicenter Phase III trial failed to confirm the efficacy of TF‐CRM107
delivered by CED. The study was stopped because an intermediate futility analysis revealed
that the chance of positive outcome was <20%.
Cintredekin besudotox (CB, also known as also known as IL13‐PE38QQR), a recombinant
chimera protein consisted of IL‐13 coupled with a truncated form of Pseudomonas exotoxin
(PE38QQR), is one of the most well‐studied targeted toxins. The toxicity and safety profile
were carefully reviewed by Kunwar and colleagues (74). Fifty‐one patients with recurrent
malignant glioma including 46 GBMs, who were infused with CB via CED after resection, were
evaluated. The treatment was well tolerated, and the adverse effects were mostly transient and
manageable. The authors categorized the adverse effects according to the onset time related
to the procedures including the placement of catheters and delivery of the agents. Three
symptomatic periods were defined: The first one was between surgery and CED; the second
was during CED and up to 7 days after infusion; and the third period was 2–10 weeks after
treatment. Adverse events including intracranial hemorrhage and infection were more likely
observed in the first period, which was related to the placement of catheters. Whereas the mass
effect due to the volume of infusion was responsible for neurological deficits during the second
period. Neurological deficits were also found in patients during the third symptomatic period.
It has been suggested that the treatment‐induced inflammation or the non‐specific toxicity for
normal brain cells resulted in the side effects. This study not only confirmed the safety of the
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delivery of CB via CED but also provided important information about the pathophysiologi‐
cal mechanism underlying the adverse events observed in the clinical trial with CED, which
is helpful to minimize the complications in further studies. A multicenter Phase III trial (Phase
III Randomized Evaluation of CED of IL13‐PE38QQR Compared to Gliadel® Wafer with
Survival End Point in GBM Patients at First Recurrence, PRECISE) investigated the efficacy of
CB infused via CED (75). Two hundred ninety‐six patients with recurrent GBM were random‐
ized to receive CED of CB or Gliadel® wafers. Unfortunately, although there was statistically
significant improvement in progression‐free survival between patients treated with CB and
those with Gliadel® wafers (17.7 vs. 11.4 weeks, p = 0.0008), no survival benefit was found, with
the median survival of 11.3 months for CB and 10 months for Gliadel® wafers for the efficacy
evaluable population (p = 0.310). But it is worth noting that 32% of catheter placements were
not performed per protocol specifications and drug distribution was not evaluated with image
monitoring. These two limitations may be possible explanation for the failure of the trial.
Lately, Sampson and colleagues (76) retrospectively analyzed the catheter positioning and
drug distribution in the PRECISE trial using BrainLAB iPlan Flow software that was not
available during the trial. The study demonstrated that more than 50% of catheters did not
meet all positioning criteria among 174 cases with sufficient data. In addition, the simulation
analysis revealed that the average coverage volume was very low, with only 20.1% of the 2‐
cm penumbra surrounding the resection cavity covered on average. Therefore, lessons learned
from PRECISE trial clearly indicate that the accurate catheter positioning and the real‐time
monitoring of drug distribution are critical for the success of interstitial drug delivery via CED.
4.3.3. Future prospects
Until now, many other agents such as monoclonal antibodies (e.g., 131I‐chTNT‐1/B mAb),
oligonucleotides (e.g., TGF‐beta2 antisense oligonucleotides) and viruses (e.g. LSFV‐IL12)
have been investigated via CED in early‐stage clinical studies (77–79) and demonstrated
benefit in selected patients. Well‐designed randomized trials are required to confirm the
efficacy. In the future, so as to fulfill an effective treatment strategy, CED will require optimized
infusates, improved catheters, standardization of catheter placement, mathematical models to
predict drug distribution, as well as the real‐time monitoring of infusate delivery.
5. Conclusion
Malignant glioma, especially GBM, is still a devastating cancer in CNS. Despite of intensive
treatment with neurosurgical resection, radiotherapy, and adjuvant chemotherapy with TMZ,
the median survival is less than 2 years. Development of novel strategies against malignant
gliomas is of urgent necessity. The advent of interstitial chemotherapy has definitely in‐
creased treatment options for patients with malignant glioma. Local delivery of chemothera‐
peutic agents bypasses the physiological barrier of normal brain, achieving a significantly
increased concentration in targeted sites and a minimized systemic toxicity. Gliadel® wafers
represent the success of interstitial chemotherapy for malignant gliomas. On the other hand,
CED is a promising approach for local drug delivery, but improvement in the techniques is
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required. In addition, novel methods such as micro‐chips and gene delivery is under investi‐
gation (80). In a word, interstitial chemotherapy conveys the opportunity of more efficiently
and effectively delivering anti‐glioma agents to the infiltrative tumors than conventional
routes of administration.
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